Norges Bank’s Kyverna Therapeutics KYTX Stock Holding History

Norges Bank’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-40,000	Closed	-$150K	–	1865
2024 Q4	$150K	Hold	40,000	–	–	﹤0.01%	1837
2024 Q3	$196K	Sell	40,000 -140,593	-78%	-$1.08M	﹤0.01%	1831
2024 Q2	$1.35M	Buy	180,593 +140,593	+351%	+$2.15M	﹤0.01%	1783
2024 Q1	$994K	Buy	+40,000	New	+$1.12M	﹤0.01%	1795

Other funds holding KYTX

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MPM

MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return

Norges Bank's KYTX Position: Q1 2025 in Review

Norges Bank sold out of Kyverna Therapeutics (KYTX) in Q1 2025, closing a stake of 40,000 shares — an estimated $150K sold.

Norges Bank first reported a position in KYTX in Q1 2024 and held it in 4 quarters. The position peaked at $1.35M in Q2 2024. 87 funds tracked by Wall St. Rank hold KYTX as of Q1 2025.

Norges Bank reported no remaining Kyverna Therapeutics position as of Q1 2025 after selling out during the quarter.
Norges Bank sold 40,000 Kyverna Therapeutics shares in Q1 2025, an estimated $150K.
Norges Bank first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 4 quarters.
Norges Bank's Kyverna Therapeutics position peaked at $1.35M in Q2 2024.
87 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2025.

Based on Norges Bank's 13F filing for Q1 2025, filed 13 May 2025.